Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 16;12(2):201.
doi: 10.3390/vaccines12020201.

A Practical Guide to Full Value of Vaccine Assessments

Caroline Trotter  1   2 , Birgitte Giersing  3 , Ann Lindstrand  3 , Naor Bar-Zeev  3 , Tania Cernuschi  3 , Lauren Franzel-Sassanpour  3 , Martin Friede  3 , Joachim Hombach  3 , Maarten Jansen  3 , Mateusz Hasso-Agopsowicz  3 , Mitsuki Koh  3 , So Yoon Sim  3 , Dijana Spasenoska  3 , Karene Hoi Ting Yeung  3 , Philipp Lambach  3
Affiliations

A Practical Guide to Full Value of Vaccine Assessments

Caroline Trotter et al. Vaccines (Basel). .

Abstract

Articulating the wide range of health, social and economic benefits that vaccines offer may help to overcome obstacles in the vaccine development pipeline. A framework to guide the assessment and communication of the value of a vaccine-the Full Value of Vaccine Assessment (FVVA)-has been developed by the WHO. The FVVA framework offers a holistic assessment of the value of vaccines, providing a synthesis of evidence to inform the public health need of a vaccine, describing the supply and demand aspects, its market and its impact from a health, financial and economic perspective. This paper provides a practical guide to how FVVAs are developed and used to support investment in vaccines, ultimately leading to sustained implementation in countries. The FVVA includes a range of elements that can be broadly categorised as synthesis, vaccine development narrative and defining vaccine impact and value. Depending on the features of the disease/vaccine in question, different elements may be emphasised; however, a standardised set of elements is recommended for each FVVA. The FVVA should be developed by an expert group who represent a range of stakeholders, perspectives and geographies and ensure a fair, coherent and evidence-based assessment of vaccine value.

Keywords: full value of vaccine assessment; vaccine development; vaccine pipeline; vaccine value.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare. Birgitte Giersing, Ann Lindstrand, Naor Bar-Zeev, Tania Cernuschi, Lauren Franzel-Sassanpour, Martin Friede, Joachim Hombach, Maarten Jansen, Mateusz Hasso-Agopsowicz, Mitsuki Koh, So Yoon Sim, Dijana Spasenoska, Karene Hoi Ting Yeung and Philipp Lambach work for the World Health Organization (WHO). The authors alone are responsible for the views expressed in this publication, and they do not necessarily represent the decisions, policy or views of the WHO.

Figures

Figure 1
Figure 1
Key elements of a Full Value of Vaccine Assessment (FVVA). The columns broadly define the purpose of each element, with the third column representing areas where most new research is likely needed to inform the FVVA.
Figure 2
Figure 2
Overarching summary of the findings from the GBS FVVA and the expected impact on key stakeholders.
Figure 3
Figure 3
Representation of the inclusive process through which stakeholders are brought together in the vaccine development-to-implementation process.
See this image and copyright information in PMC

References

    1. Carter A., Msemburi W., Sim S.Y., Gaythorpe K.A., Lambach P., Lindstrand A., Hutubessy R. Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030. Vaccine. 2023. in press . - DOI - PubMed
    1. WHO A Brief History of Vaccination. [(accessed on 30 January 2024)]. Available online: https://www.who.int/news-room/spotlight/history-of-vaccination/a-brief-h....
    1. Piot P., Larson H.J., O’Brien K.L., N’kengasong J., Ng E., Sow S., Kampmann B. Immunization: Vital progress, unfinished agenda. Nature. 2019;575:119–129. doi: 10.1038/s41586-019-1656-7. - DOI - PubMed
    1. Vekemans J., Moorthy V., Friede M., Alderson M.R., Meulen A.S.-T., Baker C.J., Heath P.T., Madhi S.A., Doare K.M.-L., Saha S.K., et al. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine. 2019;37:7391–7393. doi: 10.1016/j.vaccine.2017.09.087. - DOI - PMC - PubMed
    1. Bärnighausen T., Bloom D.E., Canning D., Friedman A., Levine O.S., O’brien J., Privor-Dumm L., Walker D. Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine. Vaccine. 2011;29:2371–2380. doi: 10.1016/j.vaccine.2010.11.090. - DOI - PubMed

LinkOut - more resources